Not provided
Not provided
Not provided
Not provided
Not provided
Poor accrual
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to compare the use of a virtual agent vs. a human agent when onboarding oncology patients over the telephone to Remote Patient Monitoring (RPM) devices. RPM devices are instruments that a patient can use to measure their own weight and vital signs. Both the virtual and human agents will be available by telephone to instruct the patient on how to use the RPM devices to measure weight, blood pressure, heart rate, temperature, and oxygen saturation. Patients will be randomized to either the virtual or human agent, have assessments of their medical and oncological history, overall well-being, body measurements, and vital signs, and will complete questionnaires about their experience.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Virtual agent | Experimental |
| |
| Human agent | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Virtual agent | Device | The virtual agent is an interactive audio agent that is similar to voice agents that interact with callers in many industries today. They create a very human-like interaction in contrast to more traditional virtual call agents that can only respond to menu options (e.g. "choose "1" for appointments, choose "2" for questions about your bill", etc.). The virtual agent is engineered to accomplish the very specific task of onboarding the patient on use of the RPM devices. It is trained to understand normal human English speech, detects emotional tone and frustration of callers, and is trained to deescalate when appropriate. |
| Measure | Description | Time Frame |
|---|---|---|
| Usability of virtual agent vs. human agent for onboarding patients to RPM devices as assessed by the System Usability Scale (SUS) | The SUS is a questionnaire that assesses perceived usability. It includes 10 five-point items with alternating positive and negative tone. The final score is a number 0-100 with a higher score indicating better usability. | Day 1, Day 2, Day 3 |
| Measure | Description | Time Frame |
|---|---|---|
| Description of the patient experience when using a virtual agent in the context of teaching a patient as assessed by the patient experience survey. | The patient experience survey includes 3 open-ended questions about experience with the training process, input on using monitoring devices at home, and any other important information for the researchers to know. Descriptive analysis will be conducted within each arm. |
Not provided
Inclusion Criteria:
Willing and able to provide written informed consent and HIPAA authorization for the release of personal health information.
Age ≥18
Cancer (solid tumor)
Planning to return to Duke Cancer Center clinic for three days in a row
Eastern Cooperative Oncology Group (ECOG) score of 0-2
Native fluency of spoken English as determined by the investigator
Vitals as collected by the clinic using Duke maintained equipment must be within the ranges specified by the remote patient monitoring devices.
Arm circumference of 22-42 cm
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Laura Alder, MD | Duke University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Duke University Medical Center | Durham | North Carolina | 27710 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D008175 | Lung Neoplasms |
| ID | Term |
|---|---|
| D012142 | Respiratory Tract Neoplasms |
| D013899 | Thoracic Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
| ID | Term |
|---|---|
| C118748 | reducing agent and tunicamycin-responsive protein, human |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Human agent | Other | The human agent will onboard the patient on use of the RPM devices. |
|
| Day 3 |
| Identification of opportunities to improve the use of a virtual agent in the context of teaching a patient as assessed by the patient experience survey. | The patient experience survey includes 3 open-ended questions about experience with the training process, input on using monitoring devices at home, and any other important information for the researchers to know. Descriptive analysis will be conducted within each arm. | Day 3 |
| D008171 |
| Lung Diseases |
| D012140 | Respiratory Tract Diseases |